Product Monograph PrCEFTIN® PrCEFTIN® - GlaxoSmithKline

anemia, including fatalities, have been reported in both adults and children. If a patient
develops anemia anytime during, or within 2-3 weeks subsequent to the administration
of CEFTIN, the diagnosis of a cephalosphorin-associated amenia should be considered
and the drug discontinued until the etiology is determined.
Patients may benefit from periodic monitoring for signs and symptoms of hemolytic
anemia, including measurement of hematological parameters or drug-induced antibody
testing, where appropriate (see PRECAUTIONS and ADVERSE REACTIONS).
General
Precautions
Broad-spectrum antibiotics including CEFTIN ® (cefuroxime axetil) should
be administered with caution to individuals with a history of gastrointestinal disease,
particularly colitis.
The concomitant administration of aminoglycosides and some cephalosporins has
caused nephrotoxicity. There is no evidence that CEFTIN ® , when administered alone, is
nephrotoxic, although transient elevations of BUN and serum creatinine have been
observed in clinical studies. However, the effect of administering CEFTIN ®
concomitantly with aminoglycosides is not known.
Studies suggest that the concomitant use of potent diuretics, such as furosemide and
ethacrynic acid, may increase the risk of renal toxicity with cephalosporins.
As with other antibiotics, use of CEFTIN ® may result in the overgrowth of Candida.
Prolonged use may also result in the overgrowth of other non-susceptible organisms
(e.g. enterococci and Clostridium difficile), which may require interruption of treatment.
November 30, 2010
Page 6 of 43